The email sent will contain a link to this article, the article title, and an article excerpt (if available). For security reasons, your IP address will also be included in the sent email.
NaturalNews) Regulators with the Food and Drug Administration have warned that Multaq, a cardiac drug
Sanofi, has been linked with fatal heart problems in a clinical trial the company recently ended.
In the study involving 3,000 patients, 32 who were taking Multaq died from cardiac-related problems compared with 14 who were taking a placebo. In all, nearly twice as many people suffered heart attacks, strokes and death than those in the placebo control group.
Multaq is prescribed to control atrial fibrillation, the most common type of irregular heartbeat which is found in about 2.2 million Americans. It is a condition in which the primary electrical impulse that
causes the atria - the two upper chambers of the
heart - to contract instead fires erratically, causing several other nodes, or electrical impulse points, to fire instead.